Skip to content
Medical Health Aged Care, Women

BCNA available to comment on landmark Advanced Breast Cancer Global Decade Report

Breast Cancer Network Australia 2 mins read
Key Facts:

Breast Cancer Network Australia (BCNA) is available to speak with media about it's role in the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025 launched today in Lisbon, Portugal.

* A decade of significant progress in metastatic (treatable but incurable) breast cancer care. 

* Highlights critical gaps and inequalities in care around the world. 

President of the General Assembly is Breast Cancer Network Australia’s Director of Policy and Advocacy, Vicki Durston. 

Key findings:

  • Five-year median overall survival for women with ABC has risen to 33%, up from 26% a decade ago
  • 79% of patients report metastatic breast cancer negatively impacts their emotional and psychological wellbeing
  • 60% of patients report financial insecurity due to treatment costs
  • 73% say the disease negatively affects their ability to work or study

 

BCNA spokespeople available for interview

* Vicki Durston, President of the General Assembly within the ABC Global Alliance. Also representing BCNA at the international conference in Portugal.

* Kirsten Pilatti, CEO, Breast Cancer Network Australia. In Melbourne

  •  

Thursday, 6th November 2025

Breast Cancer Network Australia (BCNA) is available to speak with media about the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025 and ABC Global Charter 2025–2035, launched today in Lisbon, Portugal. 

Report here

The landmark report reveals a decade of significant progress in metastatic (treatable but incurable) breast cancer care, including improved survival rates and the establishment of international consensus guidelines. However, it also highlights the critical gaps and persistent inequalities in access to treatment, support services, and workplace protections in many countries.

President of the General Assembly within the ABC Global Alliance is Breast Cancer Network Australia’s Director of Policy and Advocacy, Vicki Durston. In her role, Ms Durston represents patient groups from around the world. As a long-term member of the ABC Global Alliance, BCNA is proud of its role in impactful change.  Australia has achievements to celebrate over the past decade, but there is much more to be done to ensure anyone living with metastatic breast cancer is provided with the best care, treatment and support.

Key findings from the international report include:

  • Five-year median overall survival for women with ABC has risen to 33%, up from 26% a decade ago
  • 79% of patients report metastatic breast cancer negatively impacts their emotional and psychological wellbeing
  • 60% of patients report financial insecurity due to treatment costs
  • 73% say the disease negatively affects their ability to work or study

 

Available for interview 

Vicki Durston, President of the General Assembly within the ABC Glpbal Alliance, is representing BCNA at the international conference in Portugal.

Kirsten Pilatti, CEO, Breast Cancer Network Australia. In Melbourne

Topics for discussion

  • The implications of the report for Australians living with metastatic breast cancer
  • Australia's progress and remaining challenges in metastatic breast cancer care
  • BCNA's leaderships as the President of General Assembly representing the patient groups with the ABC Global Alliance

 

 

 

 

 


About us:

Breast Cancer Network Australia (BCNA) is the peak national organisation for Australians affected by breast cancer, and consists of a network of more than 175,000 individual members. BCNA supports, informs, represents and connects Australians affected by breast cancer and works to ensure that all Australians affected by breast cancer receive the very best care, treatment and support appropriate to their individual needs.


Contact details:

Kellie Curtain 

M: 0412339690

[email protected]

 

 

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.